Journal Watch · Science Translational Medicine · 2026

CD4<sup>+</sup> T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.

Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.

Bjornevik K, Mahler JV, Bilodeau PA et al.Science Translational Medicine3 min readPharma relevance 60/100

DOI: 10.1126/scitranslmed.adz6566PMID: 42455903Study type: cohort / observational clinical study

TL;DR

Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.

Key findings

  • Anti-CD20 therapy initiation in treatment-naïve participants reduced these responses, a finding validated in an independent cohort, and eliminated viral shedding in saliva.
  • Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.

What they did

In contrast, the Epstein-Barr nuclear antigen 1 (EBNA1) primarily activated CD8<sup>+</sup> T cells. EBV-specific CD4<sup>+</sup> T cell responses were twofold higher in individuals with untreated MS compared with healthy controls, whereas responses to other herpesviruses remained similar.

Full abstract (original)

Background: Multiple sclerosis (MS) pathogenesis is linked to Epstein-Barr virus (EBV), but the underlying immune mechanisms remain unclear. Using an optimized T cell assay, we demonstrate that CD4<sup>+</sup> T cells from individuals with MS predominantly target EBV viral particle components, specifically the late lytic capsid and glycoprotein antigens, rather than latent antigens.

What they did: In contrast, the Epstein-Barr nuclear antigen 1 (EBNA1) primarily activated CD8<sup>+</sup> T cells. EBV-specific CD4<sup>+</sup> T cell responses were twofold higher in individuals with untreated MS compared with healthy controls, whereas responses to other herpesviruses remained similar.

Results & conclusions: Anti-CD20 therapy initiation in treatment-naïve participants reduced these responses, a finding validated in an independent cohort, and eliminated viral shedding in saliva. Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.

Abstract © the authors / Science Translational Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/scitranslmed.adz6566 · PubMed 42455903.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Science Translational Medicine study find?

Our results establish preferential CD4<sup>+</sup> T cell reactivity to EBV late lytic antigens as a key feature of MS, providing a framework for developing EBV-targeted therapies, including vaccines and antivirals.

What type of study is this?

It is a cohort / observational clinical study, published in Science Translational Medicine in 2026. In contrast, the Epstein-Barr nuclear antigen 1 (EBNA1) primarily activated CD8<sup>+</sup> T cells.

Where can I read the original paper?

The original is at the publisher via DOI 10.1126/scitranslmed.adz6566. PubMed ID: 42455903. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Bjornevik K, Mahler JV, Bilodeau PA et al.. CD4&lt;sup&gt;+&lt;/sup&gt; T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.. Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.adz6566.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cd4-lt-sup-gt-lt-sup-gt-t-cells-reactive-to-epstein-barr-virus-late-lyti-dz6566/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides